Edgewise Therapeutics shareholders elect three Class II directors, ratify KPMG as auditor at 2023 annual meeting

Edgewise Therapeutics, Inc.

Laura Brege reelected with 47,325,534 votes for, 11,602,125 withheld; broker non-votes 1,064,399.
Badreddin Edris reelected with 45,321,337 for, 13,606,322 withheld; broker non-votes 1,064,399.
Jonathan Root reelected with 45,595,269 for, 13,332,390 withheld; broker non-votes 1,064,399.
Ratification of KPMG as independent auditor passed with 59,989,284 for, 2,555 against, 219 abstain.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Edgewise Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-09 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-09

Exact text from the filing

Proposal 2 : Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain 59,989,284 2,555 219 The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Edgewise Therapeutics, Inc. shareholders approved Election of three Class II Directors at the 2023-06-09 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-09

Exact text from the filing

Proposal 1: Election of three Class II Directors Name of Director For Withheld Broker Non-Votes Laura Brege 47,325,534 11,602,125 1,064,399 Badreddin Edris, Ph.D. 45,321,337 13,606,322 1,064,399 Jonathan Root, M.D. 45,595,269 13,332,390 1,064,399

View on SEC.gov

Browse all shareholder votes →

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-070064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.